Women of childbearing age represent a growing proportion of people living with HIV. Preventing pregnancy is important in HIV-infected women receiving efavirenz as part of their antiretroviral therapy.
Methods
The effects of coadministration of efavirenz (600 mg once daily) on the pharmacokinetics (PK) of the active components (ethinyl estradiol [EE] and 17-deacetyl norgestimate [NGMN]) of Ortho Cyclen® (Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ, USA) were investigated in 28 healthy HIV-negative women. The peak plasma concentration (Cmax), area under the concentration–time curve for a dosing interval (AUC[τ]), and lowest plasma concentration (Cmin) for EE and NGMN during cycles of treatment with Ortho Cyclen with and without coadministration of efavirenz were compared. Additionally, a post hoc exploratory analysis was conducted to assess the effect of efavirenz on the PK of an additional progestin, levonorgestrel (LNG).
Results
Exposures to EE were similar during coadministration of efavirenz and Ortho Cyclen to those during administration of Ortho Cyclen alone. Exposures to NGMN were substantially decreased following coadministration of efavirenz and Ortho Cyclen (adjusted geometric means for Cmax, AUC[τ] and Cmin decreased by 46%, 64% and 82%, respectively) compared with Ortho Cyclen alone. Consistent with NGMN, LNG exposures were decreased 80–86% by efavirenz.
Conclusions
Although efavirenz had no significant effect on the PK of EE, exposures to the progestin components of Ortho Cyclen, NGMN and LNG, were substantially reduced. The results reinforce the need to use reliable methods of barrier contraception, even when taking oral contraceptives and efavirenz.
References
1.
HeikinheimoO., LahteenmakiP.Contraception and HIV infection in women. Hum Reprod Update2009; 15: 165–176.
2.
FakoyaA., LambaH., MackieN.British HIV Association, BASHH and FSRH guidelines for the management of the sexual and reproductive health of people living with HIV infection 2008. HIV Med2008; 9: 681–720.
3.
HammerS.M., EronJ.J.Jr., ReissP.Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society–USA panel. JAMA2008; 300: 555–570.
4.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 4, 2009. Department of Health and Human Services (Accessed 10 December 2009.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
5.
Sustiva (efavirenz).US prescribing information2009. Bristol–Myers SquibbPrinceton, NJ, USA.
6.
Sustiva (efavirenz).Summary of product characteristics2009. Bristol–Myers SquibbUxbridge, UK.
7.
Van VlietH.A., GrimesD.A., HelmerhorstF.M., SchulzK.F.Biphasic versus triphasic oral contraceptives for contraception. Cochrane Database Syst Rev2006; 3: CD003283.
8.
MaitraN., KulierR., BloemenkampK.W., HelmerhorstF.M., GulmezogluA.M.Progestogens in combined oral contraceptives for contraception. Cochrane Database Syst Rev2004; 3: CD004861.
9.
El IbiaryS.Y., CocohobaJ.M.Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care2008; 13: 123–132.
10.
Isentress (raltegravir). US prescribing information2009. Merck & Co., Inc, Whitehouse Station, NJ, USA.
11.
KentU.M., MillsD.E., RajnarayananR.V., AlworthW.L., HollenbergP.F.Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J Pharmacol Exp Ther2002; 300: 549–558.
12.
HammondG.L., AbramsL.S., CreasyG.W., NatarajanJ., AllenJ.G., SiiteriP.K.Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception2003; 67: 93–99.
13.
PalovaaraS., PelkonenO., UusitaloJ., LundgrenS., LaineK.Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther2003; 74: 326–333.
14.
PalovaaraS., KivistoK.T., TapanainenP., ManninenP., NeuvonenP.J., LaineK.Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′-hydroxylation. Br J Clin Pharmacol2000; 50: 333–337.
15.
BelleD.J., CallaghanJ.T., GorskiJ.C.The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol2002; 53: 67–74.
16.
BaloghA., GessingerS., SvarovskyU.Can oral contraceptive steroids influence the elimination of nifedipine and its primary pryidine metabolite in humans?Eur J Clin Pharmacol1998; 54: 729–734.
17.
KuhnzW., BlodeH., MahlerM.Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women. Contraception1994; 49: 255–263.
18.
Ortho Tri-CyclenL.O. (norgestimate/ethinyl estradiol). US prescribing information2008. Ortho-McNeil-Janssen Pharmaceuticals Inc.Raritan, NJ, USA.
LondonR.S., ChapdelaineA., UpmalisD., OlsonW., SmithJ.Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand Suppl1992; 156: 9–14.
23.
WeissJ., HerzogM., KonigS., StorchC.H., Ketabi-KiyanvashN., HaefeliW.E.Induction of multiple drug transporters by efavirenz. J Pharmacol Sci2009; 109: 242–250.
24.
JosephsonF., BertilssonL., BottigerY.CYP3A induction and inhibition by different antiretroviral regimens refected by changes in plasma 4beta-hydroxycholesterol levels. Eur J Clin Pharmacol2008; 64: 775–781.
25.
ChuJ.H., GangeS.J., AnastosK.Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. Am J Epidemiol2005; 161: 881–890.
26.
CohnS.E., ParkJ.G., WattsD.H.Depomedroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther2007; 81: 222–227.
27.
NandaK., AmaralE., HaysM., ViscolaM.A., MehtaN., BahamondesL.Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril2008; 90: 965–971.
28.
WattsD.H., ParkJ.G., CohnS.E.Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception2008; 77: 84–90.
29.
MatilukoA.A., SoundararjanL., HogstonP.Early contraceptive failure of Implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz. J Fam Plann Reprod Health Care2007; 33: 277–278.
